| Year |
Citation |
Score |
| 2024 |
Gunawardhana L, Moree W, Guo J, Artur C, Womack T, Eriksen JL, Mayerich D. Fast Photostable Expansion Microscopy Using QDots and Deconvolution. Biorxiv : the Preprint Server For Biology. PMID 39651290 DOI: 10.1101/2024.11.25.625167 |
0.737 |
|
| 2022 |
Womack TR, Vollert CT, Ohia-Nwoko O, Schmitt M, Montazari S, Beckett TL, Mayerich D, Murphy MP, Eriksen JL. Prostacyclin Promotes Degenerative Pathology in a Model of Alzheimer's Disease. Frontiers in Cellular Neuroscience. 16: 769347. PMID 35197825 DOI: 10.3389/fncel.2022.769347 |
0.765 |
|
| 2020 |
Hong J, Hong SG, Lee J, Park JY, Eriksen JL, Rooney BV, Park Y. Exercise training ameliorates cerebrovascular dysfunction in a murine model of Alzheimer's Disease: Role of the P2Y2 receptor and endoplasmic reticulum stress. American Journal of Physiology. Heart and Circulatory Physiology. PMID 32383993 DOI: 10.1152/Ajpheart.00129.2020 |
0.344 |
|
| 2020 |
Guo J, Artur C, Womack T, Eriksen JL, Mayerich D. Multiplex protein-specific microscopy with ultraviolet surface excitation. Biomedical Optics Express. 11: 99-108. PMID 32010503 DOI: 10.1364/Boe.11.000099 |
0.731 |
|
| 2020 |
Womack T, Eriksen JL. Effects of Prostacyclin Signaling on Alzheimer’s Disease Associated Pathologies The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05459 |
0.729 |
|
| 2019 |
Guo J, Artur C, Eriksen JL, Mayerich D. Three-Dimensional Microscopy by Milling with Ultraviolet Excitation. Scientific Reports. 9: 14578. PMID 31601843 DOI: 10.1038/S41598-019-50870-1 |
0.329 |
|
| 2018 |
Govyadinov PA, Womack T, Chen G, Mayerich D, Eriksen J. Robust Tracing and Visualization of Heterogeneous Microvascular Networks. Ieee Transactions On Visualization and Computer Graphics. PMID 29993636 DOI: 10.1109/Tvcg.2018.2818701 |
0.717 |
|
| 2018 |
Jarvela TS, Womack T, Georgiou P, Gould TD, Eriksen JL, Lindberg I. 7B2 chaperone knockout in APP model mice results in reduced plaque burden. Scientific Reports. 8: 9813. PMID 29955078 DOI: 10.1038/S41598-018-28031-7 |
0.757 |
|
| 2018 |
Artur CG, Womack T, Zhao F, Eriksen JL, Mayerich D, Shih WC. Plasmonic nanoparticle-based expansion microscopy with surface-enhanced Raman and dark-field spectroscopic imaging. Biomedical Optics Express. 9: 603-615. PMID 29552397 DOI: 10.1364/Boe.9.000603 |
0.727 |
|
| 2016 |
Tanifum EA, Ghaghada K, Vollert C, Head E, Eriksen JL, Annapragada A. A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. Journal of Alzheimer's Disease : Jad. PMID 27031484 DOI: 10.3233/Jad-151124 |
0.428 |
|
| 2014 |
Ohia-Nwoko O, Montazari S, Lau YS, Eriksen JL. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Molecular Neurodegeneration. 9: 54. PMID 25432085 DOI: 10.1186/1750-1326-9-54 |
0.347 |
|
| 2014 |
Hoshino A, Helwig M, Rezaei S, Berridge C, Eriksen JL, Lindberg I. A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease. Journal of Neurochemistry. 128: 419-30. PMID 24102330 DOI: 10.1111/Jnc.12454 |
0.448 |
|
| 2013 |
Hazra A, Gu F, Aulakh A, Berridge C, Eriksen JL, Ziburkus J. Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. Plos One. 8: e64318. PMID 23691195 DOI: 10.1371/Journal.Pone.0064318 |
0.381 |
|
| 2013 |
Dao AT, Zagaar MA, Levine AT, Salim S, Eriksen JL, Alkadhi KA. Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. Current Alzheimer Research. 10: 507-15. PMID 23627709 DOI: 10.2174/1567205011310050006 |
0.329 |
|
| 2013 |
Helwig M, Hoshino A, Berridge C, Lee SN, Lorenzen N, Otzen DE, Eriksen JL, Lindberg I. The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. The Journal of Biological Chemistry. 288: 1114-24. PMID 23172224 DOI: 10.1074/Jbc.M112.417071 |
0.408 |
|
| 2012 |
Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, Pourgarzham H, Kamath R, Espinosa G, Cook SC, Eriksen JL, Annapragada A. Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice. Plos One. 7: e48515. PMID 23119043 DOI: 10.1371/Journal.Pone.0048515 |
0.432 |
|
| 2012 |
Alkadhi K, Eriksen J. The complex and multifactorial nature of Alzheimer's disease. Current Neuropharmacology. 9: 586. PMID 22654718 DOI: 10.2174/157015911798376235 |
0.381 |
|
| 2011 |
Sun L, Eriksen JL. Recent insights into the involvement of progranulin in frontotemporal dementia. Current Neuropharmacology. 9: 632-42. PMID 22654721 DOI: 10.2174/157015911798376361 |
0.391 |
|
| 2009 |
Cook C, Gass J, Dunmore J, Tong J, Taylor J, Eriksen J, McGowan E, Lewis J, Johnston J, Petrucelli L. Aging is not associated with proteasome impairment in UPS reporter mice. Plos One. 4: e5888. PMID 19517018 DOI: 10.1371/Journal.Pone.0005888 |
0.336 |
|
| 2008 |
Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics. 17: 3631-42. PMID 18723524 DOI: 10.1093/Hmg/Ddn257 |
0.459 |
|
| 2008 |
Eriksen JL, Zehr C, Lewis J. Biologic models of neurodegenerative disorders. Handbook of Clinical Neurology. 89: 173-88. PMID 18631742 DOI: 10.1016/S0072-9752(07)01216-X |
0.322 |
|
| 2008 |
Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, et al. Substrate-targeting gamma-secretase modulators. Nature. 453: 925-9. PMID 18548070 DOI: 10.1038/Nature07055 |
0.728 |
|
| 2008 |
Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration. Journal of Neurochemistry. 104: 287-97. PMID 17953663 DOI: 10.1111/J.1471-4159.2007.04968.X |
0.308 |
|
| 2007 |
Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends in Pharmacological Sciences. 28: 536-43. PMID 17900710 DOI: 10.1016/J.Tips.2007.09.004 |
0.391 |
|
| 2007 |
Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. Bmc Neuroscience. 8: 54. PMID 17650315 DOI: 10.1186/1471-2202-8-54 |
0.734 |
|
| 2007 |
Eriksen JL, Janus CG. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behavior Genetics. 37: 79-100. PMID 17072762 DOI: 10.1007/S10519-006-9118-Z |
0.384 |
|
| 2006 |
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, ... ... Eriksen J, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 442: 916-9. PMID 16862116 DOI: 10.1038/Nature05016 |
0.5 |
|
| 2006 |
Le Corre S, Klafki HW, Plesnila N, Hübinger G, Obermeier A, Sahagún H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 103: 9673-8. PMID 16769887 DOI: 10.1073/Pnas.0602913103 |
0.533 |
|
| 2006 |
McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends in Genetics : Tig. 22: 281-9. PMID 16567017 DOI: 10.1016/J.Tig.2006.03.007 |
0.552 |
|
| 2006 |
Lewis J, Zehr C, Andorfer C, Eriksen J, Knight J, Yue M, Robinson T, Berger Z, Hanna A, Dickson DW, Janus C, McGowan E, Hutton M. O4-05-01: Methods of cell death and recovery in the rTg4510 and iP301L inducible mouse models of tauopathy Alzheimer's & Dementia. 2: S84-S84. DOI: 10.1016/J.Jalz.2006.05.327 |
0.434 |
|
| 2006 |
Eriksen J, Zehr C, Berger Z, Robinson T, Lewis J, Hutton M. P3-293: Tau clearance through protein degradation pathways Alzheimer's & Dementia. 2: S461-S462. DOI: 10.1016/J.Jalz.2006.05.1562 |
0.478 |
|
| 2006 |
Hutton M, Melquist S, Baker M, Zehr C, McGowan E, Dickson D, Eriksen J, Ashe K, Stephan D, Lewis J. S2-02-06: The tauopathies: From genetics to animal models Alzheimer's & Dementia. 2: S26-S26. DOI: 10.1016/J.Jalz.2006.05.086 |
0.431 |
|
| 2005 |
McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 47: 191-9. PMID 16039562 DOI: 10.1016/J.Neuron.2005.06.030 |
0.731 |
|
| 2005 |
Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, Hutton M, Petrucelli L. Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. Current Alzheimer Research. 2: 231-8. PMID 15974923 DOI: 10.2174/1567205053585927 |
0.539 |
|
| 2005 |
Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nature Medicine. 11: 545-50. PMID 15834426 DOI: 10.1038/Nm1235 |
0.732 |
|
| 2004 |
Hutton M, Melrose H, Zehr C, McGowan E, Dickson DW, Yen S, Kehoe K, Taylor J, Eriksen J, Petrucelli L, Lewis J. P4-422 Mechanism of neurofibrillary degeneration in a mouse model of tauopathy and progress towards identification of a therapeutic target Neurobiology of Aging. 25: S594. DOI: 10.1016/S0197-4580(04)81978-X |
0.481 |
|
| 2004 |
Eriksen J, Kehoe K, Taylor J, Hutton M, Petrucelli L. P3-389 HSP70 prevents α-synuclein inhibition of the proteasome Neurobiology of Aging. 25: S466. DOI: 10.1016/S0197-4580(04)81537-9 |
0.432 |
|
| 2004 |
Pickford F, Onstead-Cardinale L, Eriksen J, Murphy P, Pritam D, Kim J, Dolios G, Wang R, Dickson DW, Golde T, McGowan E. P2-090 ABETA42 is required for amyloid deposition in transgenic mice Neurobiology of Aging. 25: S249. DOI: 10.1016/S0197-4580(04)80837-6 |
0.558 |
|
| 2004 |
Golde TE, Eriksen J, Nicolle M, Murphy MP, Kukar T, Monnier T, Prescott S, Wright S, Chevallier N, Sagi S, Das P, Koo EH. O3-06-02 Selective Abeta42 modifying agents: effects on Abeta deposition and behavior in TG2576 mice Neurobiology of Aging. 25: S64. DOI: 10.1016/S0197-4580(04)80215-X |
0.716 |
|
| 2004 |
Eriksen JL, Petrucelli L. Parkinson's disease - Molecular mechanisms of disease Drug Discovery Today: Disease Mechanisms. 1: 399-405. DOI: 10.1016/J.Ddmec.2004.11.016 |
0.311 |
|
| 2003 |
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. The Journal of Clinical Investigation. 112: 440-9. PMID 12897211 DOI: 10.1172/Jci18162 |
0.576 |
|
| 2003 |
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. The Journal of Biological Chemistry. 278: 31831-7. PMID 12805356 DOI: 10.1074/Jbc.M303592200 |
0.511 |
|
| 2003 |
Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. The Journal of Biological Chemistry. 278: 31825-30. PMID 12805355 DOI: 10.1074/Jbc.M303588200 |
0.526 |
|
| 2003 |
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. The Journal of Biological Chemistry. 278: 30748-54. PMID 12777371 DOI: 10.1074/Jbc.M304824200 |
0.553 |
|
| 2002 |
Golde TE, Eriksen JL, Weggen S, Sagi SA, Koo EH. Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease Drug Development Research. 56: 415-420. DOI: 10.1002/Ddr.10093 |
0.563 |
|
| 2001 |
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414: 212-6. PMID 11700559 DOI: 10.1038/35102591 |
0.573 |
|
| Show low-probability matches. |